First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $ (0.2) billion and GAAP EPS of $ (0.51) Improves 2025 ...
Dynavax Technologies Corporation , a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, and Vaxart, Inc. , a clinical-stage biotechnology company developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback